Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis
Go back to Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis| (NASDAQ: SVRA) | Delayed: 5.78 +0.09 (1.58%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.69 | 52 Week High | $ | |||
| Open | $5.64 | 52 Week Low | $ | |||
| Day High | $5.90 | P/E | N/A | |||
| Day Low | $5.60 | EPS | $ | |||
| Volume | 1,856,693 | |||||
